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Prevention of Cardiac Dysfunction in Acute Coxsackievirus
B3 Cardiomyopathy by Inducible Expression of a Soluble
Coxsackievirus-Adenovirus Receptor
Sandra Pinkert, MSc; Dirk Westermann, MD; Xiaomin Wang, BSc; Karin Klingel, MD;
Andrea Dörner, PhD; Konstantinos Savvatis, MD; Tobias Größl, MSc; Stefanie Krohn, MSc;
Carsten Tschöpe, MD; Heinz Zeichhardt, PhD; Katja Kotsch, PhD; Kerstin Weitmann, MSc;
Wolfgang Hoffmann, MD; Heinz-Peter Schultheiss, MD; O. Brad Spiller, PhD;
Wolfgang Poller, MD; Henry Fechner, DVM
Background—Group B coxsackieviruses (CVBs) are the prototypical agents of acute myocarditis and chronic dilated
cardiomyopathy, but an effective targeted therapy is still not available. Here, we analyze the therapeutic potential of a
soluble (s) virus receptor molecule against CVB3 myocarditis using a gene therapy approach.
Methods and Results—We generated an inducible adenoviral vector (AdG12) for strict drug-dependent delivery of
sCAR-Fc, a fusion protein composed of the coxsackievirus-adenovirus receptor (CAR) extracellular domains and the
carboxyl terminus of human IgG1-Fc. Decoy receptor expression was strictly doxycycline dependent, with no
expression in the absence of an inducer. CVB3 infection of HeLa cells was efficiently blocked by supernatant from
AdG12-transduced cells, but only in the presence of doxycycline. After liver-specific transfer, AdG12 (plus
doxycycline) significantly improved cardiac contractility and diastolic relaxation compared with a control vector in
CVB3-infected mice if sCAR-Fc was induced before infection (left ventricular pressure 593.8 versus
45.42.7 mm Hg, median 59 versus 45.8 mm Hg, P0.01; dP/dtmax 3645.1443.6 versus 2057.9490.2 mm Hg/s,
median 3526.6 versus 2072 mm Hg/s, P0.01; and dP/dtmin 2125.5330.5 versus 1310.2330.3 mm Hg/s, median
2083.7 versus 1295.9 mm Hg/s, P0.01) and improved contractility if induced concomitantly with infection (left
ventricular pressure 76.419.2 versus 56.810.3 mm Hg, median 74.8 versus 54.4 mm Hg, P0.05; dP/dtmax
5214.21786.2 versus 3011.6918.3 mm Hg/s, median 5182.1 versus 3106.6 mm Hg/s, P0.05), respectively.
Importantly, hemodynamics of animals treated with AdG12 (plus doxycycline) were similar to uninfected controls.
Preinfection induction of sCAR-Fc completely blocked and concomitant induction strongly reduced cardiac CVB3
infection, myocardial injury, and inflammation.
Conclusion—AdG12-mediated sCAR-Fc delivery prevents cardiac dysfunction in CVB3 myocarditis under prophylactic
and therapeutic conditions. (Circulation. 2009;120:2358-2366.)
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Coxsackievirus B3 (CVB3), a member of the enterovirusgroup of Picornaviridae, is one of the most commonly
identified infectious agents associated with acute and chronic
myocarditis1; it can also mediate infectious pancreatitis and
meningitis. Acute enteroviral myocarditis may not lead to
initial mortality, but there is strong evidence to show that it
often leads to the insidious development of dilated cardiomy-
opathy.1 Currently, enteroviral myocarditis is treated nonspe-
cifically by palliative care, because no effective antiviral
therapy is available. CVB load, replication, and persistence
are directly associated with cardiac injury and progression of
the disease.2,3 A direct cytopathic effect of CVB in vitro and
the induction of cardiac injury in immunodeficient mice in vivo
support the significance of direct virus-mediated cardiac injury
in disease pathogenesis.4 Specific targeting of CVB in viral
myocarditis, therefore, will not only abrogate virus-mediated
direct cardiac damage but will diminish immune response–
mediated damage by blocking viral spread to uninfected tissue.
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The coxsackievirus-adenovirus receptor (CAR) mediates
cellular attachment for adenovirus subtypes A and C through
F and is essential to permit infection of all 6 serotypes of
CVB.5 CAR is a member of the immunoglobulin superfamily
that consists of 2 extracellular immunoglobulin-like domains
(D1 and D2), a transmembrane domain, and an intracellular
tail of variable length.6 The N-terminal D1 domain has been
shown to bind both adenovirus fiber knob protein and the
canyon structure of CVB capsids.7,8 Soluble decoy viral
receptors have been found to efficiently inhibit infection by
rhinoviruses, measles viruses, and adenoviruses.9–11 Soluble
CAR (sCAR) proteins inhibit CVB infection of susceptible
target cells in vitro and in vivo.12,13 The interaction of CVB3
with sCAR leads to formation of altered particles that are
characterized by loss of VP4 from the virion shell and
subsequent irreversible loss of infectivity.14,15 However, se-
vere side effects, with increased cardiac inflammation and
heart injury, have been observed after treatment of CVB3-
infected mice with CAR4/7, a native sCAR variant with an
intact CVB3-binding D1 domain, half of the D2 domain, and
a 23–amino acid–long C-terminus.16
Previous investigations have shown that dimeric sCAR,
expressed as an immunoglobulin Fc-region fusion protein,
has reduced systemic clearance and increased virus-
neutralizing capacity relative to monomeric sCAR and does
not induce undesirable side effects.14 Therefore, the aim of
the present study was to create an in vivo delivery system that
would express sCAR-Fc in the liver for systemic release
under the tight control of an inducible promoter. An adeno-
viral vector (AdV) was constructed that only expressed
sCAR-Fc in the presence of doxycycline (Dox). It was our
primary hypothesis that delivery of sCAR-Fc via a recombi-
nant adenovirus expression vector to CVB3-infected animals
would inhibit myocardial CVB3 infection and improve car-
diac function relative to CVB3-infected animals treated with
a vector control. We used hemodynamic indices as the best
measure of cardiac function and histological measurements to
monitor cardiomyopathy after CVB3 infection.
Methods
Coxsackievirus B3
In vitro and in vivo experiments used the genetically characterized,
cardiovirulent Nancy strain of CVB3.17 Methods detailing virus propa-
gation and titration of CVB3 in HeLa cells, as well as storage at80°C,
before infection of cells or animals have been published previously.13
Development of AdVs
sCAR-Fc was generated by fusion of the extracellular domain of
human CAR with the carboxy terminus of the human IgG1 Fc coding
region and inserted into an adenoviral shuttle plasmid that contained
improved elements of the Tet-On gene expression system in different
configurations. AdVs were generated as described previously.18
Details of cloning strategies and adenoviral generation are provided
in the online-only Data Supplement.
Cell Cultures, Northern Blot, Western Blot, Virus
Plaque Assays, and IgG ELISA
HeLa (human cervical carcinoma) cells and HEK293 (human em-
bryonic kidney) cells were cultured in Dulbecco’s modified Eagle’s
medium (Gibco BRL, Karlsruhe, Germany) supplemented with 10%
FCS and 1% penicillin/streptomycin. Northern and Western blot
analysis and virus plaque assays were performed as described
previously.18 Human IgG ELISA (Bethyl Laboratories Inc, Mont-
gomery, Tex) for detection of the Fc tail of sCAR-Fc was performed
according to the supplier’s instructions. Details are provided in the
online-only Data Supplement.
Murine CVB3 Myocarditis
AdG12 was injected into the jugular vein of 6- to 8-week-old
BALB/c mice. Two days after AdV injection, mice were infected
with 5104 plaque-forming units (pfu) of CVB3 intraperitoneally.
Doxycycline (200 g/mL) was administered orally to the mice via
drinking water 2 days before CVB3 infection (prophylactic ap-
proach) or concomitantly with or 1 day after CVB3 infection
(therapeutic approach). The water was replaced daily by fresh water
that contained doxycycline. Seven days after CVB3 infection, the
hemodynamic parameters of the mice were analyzed as described
previously,19 then blood was taken and organs were harvested for
histopathological analysis. CVB3 positive-strand genomic RNA in
tissues was detected by in situ hybridization with single-stranded
35S-labeled RNA probes as described previously20 or standard plaque
assay for CVB3 as described previously.19 All animals investigated
in the present study were inbred male mice with identical genomes.
For this reason, no special randomization algorithm was used. The
investigation was performed in accordance with the principles of
laboratory animal care and the German law on animal protection.
Statistical Analysis
Statistical analysis of the in vivo measurements was performed with
SAS version 9.1 (SAS Institute Inc, Cary, NC). Nonnormally
distributed parameters (left ventricular pressure [LVP], dP/dtmax,
dP/dtmin, and virus load in the heart) are described as mean, SD,
median, and 25th and 75th percentiles. Prespecified 2-group com-
parisons [sham (Dox) versus sham (Dox), AdG12 (Dox)
versus AdG12 (Dox)] of the medians of nonnormally distributed
data were performed by Mann–Whitney U test. The option “exact”
for small sample sizes was selected (procedure: npar1way). Fisher’s
exact test was used for analysis of differences between myocarditis
scores. Differences were considered significant at P0.05.
Results
Doxycycline-Dependent Regulation of
sCAR-Fc Therapy
To achieve doxycycline-dependent sCAR-Fc expression, 2
AdVs were constructed. Each AdV contained 2 expression
cassettes, 1 for constitutive expression of the second-generation
reverse tetracycline transactivator rtTA-M2,21 the other for
expression of sCAR-Fc from the improved second-generation
tetracycline response promoter tight1.22 The expression cassettes
were inserted either in tandem orientation (AdR4) or in opposite
orientations (AdG12) into the E1 region of an E1-deleted,
E3-deleted adenovirus 5 backbone (Figures 1A and 1B). To
analyze doxycycline-dependent regulation of AdV-mediated
sCAR-Fc expression, HeLa cells were transduced with AdR4 or
AdG12 and cultured in the presence or absence of doxycycline.
Northern blot analysis found sCAR-Fc mRNA expression to be
strictly doxycycline dependent, whereas rtTA-M2 expression
was constitutively high (Figure 2A). However, as detected by
phosphorimaging of Northern blots (Figure 2A), doxycycline-
induced sCAR-Fc mRNA expression was up to 6-fold higher in
AdG12- than in AdR4-transduced cells. Therefore, AdG12 was
selected for further in vitro and in vivo studies.
sCAR-Fc protein was only detectable in AdG12-transduced
cells and in the cell culture supernatant in the presence of
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doxycycline (Figure 2B, left). As expected, Western blot anal-
ysis (under nonreducing conditions) confirmed that sCAR-Fc
was expressed as a dimeric protein (Figure 2B, right). Further-
more, rapid doxycycline-dependent on/off switching of
sCAR-Fc expression from AdG12 could be confirmed (Figure I
in the online-only Data Supplement).
Inhibition of CVB3 Infection by AdG12 In Vitro
Next, we studied sCAR-Fc–mediated inhibition of CVB3 in
vitro as a function of AdG12 dose, doxycycline concentra-
tion, and the dose of CVB3. Transduction of HeLa cells with
5 multiplicities of infection (MOI) of AdG12 and induction
with doxycycline 500 ng/mL for 48 hours were sufficient to
prevent CVB3 infection in sCAR-Fc–expressing cells com-
pletely. Under these transducing conditions, sCAR-Fc ex-
pression levels reached a maximum with 29.4 g/mL in the
cell culture supernatant. sCAR-Fc expressed from AdG12
efficiently blocked CVB3 doses of up to 2.5 MOI (Figures
IIA through IID in the online-only Data Supplement). There-
fore, sCAR-Fc expressed by AdG12-transduced cells effi-
ciently inhibited CVB3 infection of these cells, and secreted
sCAR-Fc levels were directly related to initial AdG12 MOI
and doxycycline concentration.
To assess the potential of AdG12 to suppress ongoing
infections, which represents the typical situation encountered
in the clinical setting, HeLa cells were transduced with
AdG12, and sCAR-Fc expression was induced with doxycy-
cline at different times relative to CVB3 infection. Expression
of sCAR-Fc 48 and 24 hours before CVB3 infection resulted
in complete inhibition of CVB3 infection in the transduced
cells. The inhibitory efficiency of sCAR-Fc was gradually
reduced the later the sCAR-Fc expression was induced.
However, even if sCAR-Fc expression was induced 24 hours
after infection, CVB3 progeny virus number was still reduced
approximately 106-fold compared with controls without
sCAR-Fc (Figure 3), which demonstrates the high efficacy of
sCAR-Fc in ongoing CVB3 infections.
Preinfection sCAR-Fc Gene Therapy Prevents
Cardiac Dysfunction and Inflammation
Encouraged by the in vitro data, we tested the ability of
AdG12-transduced mice to inhibit CVB3-mediated myocar-
Figure 1. Structure of sCAR-Fc–ex-
pressing AdVs and mechanism of sCAR-
Fc–mediated CVB3 inhibition. A, Sche-
matic of doxycycline-regulated sCAR-
Fc–expressing AdVs AdG12 and AdR4.
Two expression cassettes, 1 for expres-
sion of the doxycycline-dependent trans-
activator rtTA-M2 and the other for
doxycycline-inducible expression of
sCAR-Fc, were inserted into the E1
region between nucleotide positions 453
and 3333 of an E1-deleted, E3-deleted
adenovirus 5 backbone. AdR4 contains
the 2 expression cassettes in a tandem
direction, whereas in AdG12, the cas-
settes were inserted in opposite orienta-
tions. B, Mechanism of doxycycline-
dependent adenoviral expression of
sCAR-Fc and sCAR-Fc–mediated inhibi-
tion of CVB3 infection. In the absence of
doxycycline, rtTA-M2 is unable to trans-
activate the tight1 promoter; therefore,
sCAR-Fc is not expressed, and CVB3
infection cannot be inhibited (top). In the
presence of doxycycline, rtTA-M2 trans-
activates the tight1 promoter, and
sCAR-Fc is expressed and neutralizes
CVB3 (bottom). CMV IE p indicates
immediate-early CMV promoter; rtTA,
reverse tetracycline-controlled transacti-
vator rtTA-M2; tight1, doxycycline-
dependent response promoter; sCAR-
Fc, fusion protein of the soluble
extracellular domain of human CAR and
the human IgG1 Fc region; SV40 pA and
bGH pA, polyadenylation signal of SV40
and bovine growth hormone; 5ITR, nu-
cleotide positions 1 to 453 of adenovirus
type 5 containing the left inverted termi-
nal repeat of adenovirus 5 and the pack-
aging signal ; and 3ITR, right inverted
terminal repeat of adenovirus 5.
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ditis. Mice were transduced with AdG12, and sCAR-Fc
expression was induced and maintained via constant oral
doxycycline administration. The AdG12 dose was reduced to
11010 virus particles per mouse because initial experiments
with 31010 particles of AdG12 (Figure IIIA in the online-
only Data Supplement) resulted in sCAR-Fc serum levels that
easily exceeded therapeutic levels, previously identified to be
100 ng/mL.11 Two days after vector transduction, animals
were infected with 5104 pfu of CVB3 (Figure 4A). At the
point of CVB3 infection, circulating sCAR-Fc concentrations
were 228.5174 ng/mL, and 7 days later, when mice were
euthanized, sCAR-Fc concentrations were 99.6322.7 ng/
mL. No sCAR-Fc was measured in the AdG12-transduced
mice that did not receive doxycycline, which were identical to
animals that did not receive AdG12. CVB3-infected mice that
did not receive AdG12 or were transduced with AdG12 in the
absence of doxycycline administration showed a continuous
loss in body weight, which resulted in an average 30%
decrease by day 7 after infection. By comparison, CVB3-
infected mice that received AdG12 and doxycycline only lost
roughly 5% of their body weight (Figure IVA in the online-
only Data Supplement). Hemodynamics were measured by
tip catheter on day 7 after CVB3 infection. AdG12 (Dox)–
treated CVB3-infected mice had significantly improved cardiac
contractility and diastolic relaxation compared with CVB3-
infected animals transduced with AdG12 in the absence of
doxycycline (LVP 593.8 versus 45.42.7 mm Hg, median 59
versus 45.8 mm Hg, P0.01; dP/dtmax 3645.1443.6 versus
2057.9490.2 mm Hg/s, median 3526.6 versus 2072 mm Hg/s,
P0.01; dP/dtmin2125.5330.5 versus1310.2330.3 mm Hg/
s, median 2083.7 versus 1295.9 mm Hg/s, P0.01). Impor-
tantly, hemodynamics of CVB3-infected animals treated with
AdG12 (Dox) were similar to noninfected control animals
(Figure 4B). For statistical details, see Tables IA and IB in the
online-only Data Supplement. Myocardial histological grading
revealed extensive areas of damage, with myocyte necrosis and
infiltration of mononuclear cells in CVB-infected control mice
and in CVB3-infected AdG12 (Dox) mice (myocarditis score
of 3 to 4 in both groups). Cell damage and inflammation were
completely absent in the AdG12 (Dox) group (myocarditis
score0) and showed histology comparable to that of hearts of
noninfected control mice (Figure 4C).
Preinfection sCAR-Fc Gene Therapy Inhibits
CVB3-Mediated Cardiomyopathy and Pancreatitis
To document whether the absence of pathological changes of
the heart correlated with cardiac CVB3 infection, we per-
formed radioactive in situ hybridization experiments to visu-
alize the presence of positive-strand CVB3 RNA at the
cellular level with a high sensitivity. Animals in the AdG12
(Dox) CVB3-infected group did not show any CVB3-
infected cells in the heart and no (Figure 4D) or minimal
(results not shown) levels of CVB3 RNA in the pancreas,
Figure 2. Doxycycline (Dox)-dependent
expression of sCAR-Fc by AdG12. A,
Expression of sCAR-Fc mRNA. HeLa cells
were transduced with AdG12 and AdR4,
each at an MOI of 2, and then cultured in
the presence and absence of doxycycline.
Northern blot analysis performed 48 hours
after transduction showed a doxycycline
dose–dependent increase of sCAR-Fc
mRNA expression for both vectors,
whereas rtTA-M2 expression remained
constant. sCAR-Fc transcription could not
be detected in the absence of doxycy-
cline. B, Expression of sCAR-Fc protein.
HeLa cells were transduced with AdG12,
and sCAR-Fc expression was induced as
described in (A) above. sCAR-Fc was
detected by Western blot analysis (reduc-
ing conditions) in both cells and cell cul-
ture supernatant with antibodies directed
against human CAR and the human
IgG-Fc domain. Immunoreactivity against
GAPDH was used as a loading control
(left). Right, Dimeric sCAR-Fc detected by
Western blotting under nonreducing con-
ditions in cell culture supernatant.
Figure 3. Inhibition of ongoing CVB3 infection by sCAR-Fc.
HeLa cells were transduced with AdG12 at an MOI of 5. Forty-
eight hours later, cell culture supernatant was harvested, prein-
cubated with CVB3 (MOI 0.01 to 0.00001) for 30 minutes at
4°C, deposited to the AdG12-transduced cells for 30 minutes,
and then replaced with fresh medium. CVB3 replication was an-
alyzed by plaque assays after 48 hours of culture. For induction
of sCAR-Fc expression, doxycycline (Dox; 1 g/mL) was added
to the medium at the time points indicated, from 48 hours
before to 24 hours after CVB3 infection.
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which is the primary site of CVB replication and the most
susceptible organ for CVB infection in mice. In contrast,
CVB3-infected and AdG12 (Dox) CVB3-infected mice
showed high prevalence of CVB3 RNA in the heart and
pancreas. In other organs (spleen, liver, kidney, intestine, and
lung), CVB3 RNA was undetectable in AdG12 (Dox) and in
the control groups by in situ hybridization (Figure 4D). Thus,
sCAR-Fc efficiently protected mice from virus entry and subse-
quent replication in the heart and other organs.
Therapeutic sCAR-Fc Gene Therapy Improves
Cardiac Contractility and Reduces Cardiomyopathy
We next analyzed the efficacy of sCAR-Fc gene therapy in a
therapeutic approach. Mice were transduced with AdG12,
and doxycycline-mediated induction of sCAR-Fc was de-
layed either to be concomitant with CVB3 infection (2 days
after transduction) or to occur 1 day after CVB3 infection
(day 3 after transduction; Figure 5A). By use of this experi-
mental approach, low levels of sCAR-Fc (28.4 ng/mL) were
just detectable at 16 hours after induction (ie, either 16 hours
or 40 hours after CVB infection for the 2 groups, respec-
tively; Figure IIIB in the online-only Data Supplement). Body
weights for the concomitant-induction group were reduced by
an average of 4%, whereas body weights for the 1-day
delayed-induction group decreased by an average of 14% and
that of untreated CVB3-infected controls decreased by an
average of 18% by day 7 after infection (Figure IVB in the
online-only Data Supplement). Compared with CVB3-infected
animals transduced with the control vector AdG12trunc, which did
not expresses sCAR-Fc, induction of sCAR-Fc concomitant
with CVB3 infection led to significantly improved cardiac
contractility (LVP 76.419.2 versus 56.810.3 mm Hg, me-
dian 74.8 versus 54.4 mm Hg, P0.05; dP/dtmax 5214.21786.2
versus 3011.6918.3 mm Hg/s, median 5182.1 versus
3106.6 mm Hg/s, P0.05), with values that surprisingly were in
the range of uninfected control animals. The diastolic relaxation
in the CVB3-infected group with concomitant sCAR-Fc expres-
sion showed no significant improvement relative to control vector–
transduced animals but revealed a clear trend toward improvement
(dP/dtmin 3756.61418 versus 2212745.7 mm Hg/s, median
3624.3 versus 2217.43 mm Hg/s, P0.073). However, ani-
mals with induced sCAR-Fc expression 1 day after CVB3
infection did not show improved hemodynamics (Figure 5B).
For statistical details, see Tables IIA and IIB in the online-only
Figure 4. Effects of AdG12-mediated preinfection
sCAR-Fc expression on murine CVB3 myocarditis.
A, Application scheme and timeline of sample prepa-
ration. Eleven mice were transduced with 11010
particles of AdG12, and sCAR-Fc expression was
induced and maintained through doxycycline (Dox) in
5 of the 11 animals. Twelve control mice were sham
operated, and 6 of them were treated with doxycy-
cline. AdG12 (Dox), AdG12 (Dox), and sham-
operated (Dox) animals were infected with 5104
pfu of CVB3 2 days later and analyzed 7 days after
CVB3 infection. Sample sizes: Sham (Dox), n6;
sham (Dox), n6; AdG12 (Dox), n5; AdG12
(Dox), n6. B, Effect of sCAR-Fc and CVB3 infec-
tion on cardiac function. Left ventricular function in
CVB3-infected animals was severely disturbed, with
impaired contractility (LVP, dP/dtmax) compared with
sham-operated controls without CVB3 infection. The
AdG12 (Dox) group had significantly improved sys-
tolic and diastolic left ventricular function compared
with the AdG12 (Dox) group. **P0.01, #P0.065.
Values are medians; () indicates the mean. C,
AdG12 reduces CVB3-mediated cardiomyopathy.
Top, 100-fold magnification. Bottom,, 200-fold mag-
nification. Heart sections were stained with hematox-
ylin and eosin. The AdG12 (Dox) group exhibited
complete preservation of myocardial integrity,
whereas in AdG12 (Dox) and sham-operated
(Dox) control animals, extensive areas with myo-
cyte necrosis and inflammation were prominent.
Arrows represent extensive areas of inflammation. D,
Virus entry into and replication in the heart and pan-
creas are blocked by sCAR-Fc. The distribution of
viral RNA was visualized by in situ hybridization with
a 35S-labeled RNA probe specific to CVB3. In CVB3-
infected sham-operated (Dox) control mice, cardio-
myocytes were infected as indicated by the black
precipitate, which represents the virus RNA. CVB3
infection was also detected in pancreas, whereas
spleen, lung, gut, kidney, and liver were not infected.
No virus-positive cells could be detected in AdG12
(Dox) mice in any of the organs investigated,
whereas in AdG12 (Dox), a similar organ distribu-
tion of CVB3 infection as in CVB3-infected sham-
operated (Dox) control mice was observed.
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Data Supplement. Myocardial pathological grading revealed
reduced myocarditis scores in both the concomitant and postin-
fection sCAR-Fc treatment groups (Figure 5C) and significantly
decreased infectious CVB3 titers in the heart compared with
CVB3-infected control animals (Figure 5D). For statistical
details, see Tables IIC and IID in the online-only Data Supple-
ment. However, all animals in these groups with sCAR-Fc
expression after CVB3 infection showed high pathological
scoring and inflammatory damage to the pancreas (pancreatitis
score 3 to 4; not shown), which indicates that only prophylaxis
was capable of saving the pancreas from destruction.
Discussion
In the present study, we report inhibition of CVB3 infection
by a sCAR-Fc fusion protein expressed from the newly
developed doxycycline-regulated adenovector AdG12.
sCAR-Fc expressed from AdG12 inhibited CVB3 infection
of susceptible target cells in vitro and inhibited CVB3
Figure 5. AdG12-mediated therapeutic sCAR-Fc
expression in murine CVB3 myocarditis. A, Appli-
cation scheme and timeline of sample preparation.
Twelve mice were transduced with 11010 parti-
cles of AdG12 and infected with CVB3 2 days
later. sCAR-Fc expression was induced through
doxycycline (Dox) in 5 animals concomitantly with
(AdG12 Dox, 0d) and in 7 animals 1 day after
(AdG12 Dox, 1d) CVB3 infection, respectively.
Seven mice were transduced with 11010 particles
of the control AdV (AdG12trunc Dox), which has
overall sequence identity to AdG12 but does not
express sCAR-Fc, and infected with CVB3 2 days
after transduction. Eleven mice were sham oper-
ated, and 4 of them were treated with doxycycline
and infected with CVB3 (sham Dox). Sample
size: AdG12 (Dox, 0d), n5; AdG12 (Dox, 1d),
n7; AdG12trunc (Dox), n7; sham (Dox), n4;
sham (Dox), n7. B, Effect of sCAR-Fc and
CVB3 infection on cardiac function. Left ventricular
function in CVB3-infected untreated animals was
severely disturbed, with impaired contractility (LVP,
dP/dtmax) and relaxation (dP/dtmin) compared with
sham-operated controls without CVB3 infection.
The AdG12 (Dox, 0d) group had significantly
improved systolic left ventricular function com-
pared with the control vector AdG12trunc (Dox)–
transduced group. *P0.05, #P0.073. Values are
medians; () indicates the mean. C, AdG12 medi-
ates reduced cardiomyopathy. Left, Myocarditis
score of CVB3-infected and sCAR-Fc–treated
groups. Shown are frequencies of myocarditis
score weighted with number of animals. Myocar-
dial pathological grading revealed significantly
reduced myocarditis score in both the concomi-
tant and postinfection sCAR-Fc treatment groups.
**P0.01. Right, Heart sections were stained with
hematoxylin and eosin. The AdG12 (Dox, 0d) and
(Dox, 1d) groups exhibited complete preserva-
tion of myocardial integrity, whereas in AdG12trunc
(Dox) and sham (Dox) control animals, exten-
sive areas with myocyte necrosis and inflammation
were prominent. Arrows represent areas of inflam-
mation. Original magnification 200. D, AdG12
reduces parenchymal viral load. Left, Cardiac tis-
sue samples were homogenized, and viral titers
were assessed by plaque assay. Values shown are
meanSEM. **P0.01; ***P0.001. Right, Distri-
bution of viral RNA was visualized by in situ
hybridization with a 35S-labeled RNA probe spe-
cific to CVB3. Black precipitates represent
CVB3-RNA.
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infection of the myocardium in vivo. As a consequence,
sCAR-Fc prevented heart injury and cardiac inflammation
and prevented the development of systolic and diastolic
cardiac dysfunction in CVB3-infected animals.
Previous reports demonstrated inhibition of CVB3 myo-
carditis through application of purified recombinant sCAR-
Fc13 or through delivery of sCAR-Fc from plasmids.11 How-
ever, plasmid-based transgene expression in vivo is
inefficient owing to low-level and transient protein expres-
sion, which severely limits its use in acute CVB3 infections
with high virus load.11 Furthermore, methods that are used to
enhance plasmid uptake, eg, electroporation, appear to be
inapplicable for therapeutic use in humans. Generation of
purified recombinant proteins is time consuming and expen-
sive, and ex vivo production of the proteins in bacterial or
mammalian cells runs the risk of copurifying proinflamma-
tory substances (ie, lipopolysaccharide) or altering the glyco-
sylation of proteins that accelerate their systemic clearance.
Moreover, repeated readministration frequently is necessary
to maintain therapeutic protein levels for both the plasmid-
based and the recombinant protein approach.
Therefore, we focused on the development of a gene
therapy approach that used an AdV as a carrier to deliver
sCAR-Fc. This viral vector type enables fast, strong, persis-
tent expression of therapeutic genes in vivo. Intravenous
AdG12 application resulted in a typical expression profile of
sCAR-Fc after its doxycycline-mediated induction with the
highest sCAR-Fc serum levels at days 4 and 5 after induction.
Most importantly, sCAR-Fc was already detectable in the
serum 16 hours after induction with doxycycline, and serum
levels rapidly increased to 	100 ng/mL within 1 day after
transduction. These levels exceeded serum sCAR-Fc levels
measured after plasmid-based gene transfer, and moreover,
they exceeded the sCAR-Fc serum concentration that has
been shown to be required to protect animals from CVB3-
induced myocarditis.11 In addition, if the AdG12 dose of
11010 particles used for mice is adapted to human weight, it
would be within the range of AdV doses previously used in
clinical trials, which suggests that therapeutically relevant
sCAR-Fc serum levels could be produced in humans after
AdG12 treatment.
CVB3 infection is known to evoke severe left ventricular
systolic and diastolic failure in humans during acute infec-
tion23 and in the present well-established experimental mod-
el.24 Here, we confirm cardiac dysfunction in CVB3-infected
mice as reduced left ventricular contractility and relaxation.
The present study demonstrates for the first time that
CVB3-induced cardiac failure can be prevented by sCAR-Fc,
because the hemodynamic parameters (LVP, dP/dtmax, and
dP/dtmin) of sCAR-Fc–expressing AdG12 (Dox)–treated
mice were significantly better than those of untreated CVB3-
infected mice, almost reaching the values measured in unin-
fected control animals. The effect was visible when sCAR-Fc
was expressed prophylactically, but much more importantly,
LVP and dP/dtmax were also improved if sCAR-Fc was
induced concomitantly with CVB3 infection, which demon-
strates a strong potential for therapeutic efficacy of the
sCAR-Fc gene therapy approach after CVB3 infection. Al-
though sCAR-Fc induction corresponding to approximately
40 hours after CVB3 infection did not improve heart function
or pancreatitis, histological cardiomyopathy grading and
myocardial virus load were decreased significantly, which
likely would lessen the risk of development of dilated
cardiomyopathy. In agreement with previous reports,11,25
prophylactic sCAR-Fc delivery abrogated pancreatic and
cardiac inflammation and necrosis and resulted in negligible
virus load as assessed by in situ visualization of CVB3
genome presence and parenchymal virus titer. The present
study improves on previous methods of delivering sCAR-Fc
by showing higher and more prolonged circulating levels of
decoy receptor, without the variability of plasmid delivery or
expense and potential copurification of contaminants associ-
ated with the production of purified recombinant proteins.
The decreased efficacy of sCAR-Fc gene therapy when
administered after CVB3 infection likely reflects the inability
of sCAR-Fc to penetrate sufficiently into the parenchyma of
the heart and pancreas once initial virus infection has been
established and the virus predominantly spreads between
adjacent cells or perhaps is unable to fully neutralize the
initially high levels of CVB3 in the serum that are seen early
in infection.26 The present results were similar to those
previously reported that examined administration of purified
recombinant sCAR-Fc13 to CVB3-infected mice, but the
present results advance these studies by showing a significant
decrease in cardiac inflammation, virus load, and cardiac
function if treatment begins within the first 24 hours of CVB
infection.
The present in vitro data demonstrate that sCAR-Fc could
neutralize up to 104 CVB3 particles (results not shown) and
reduce CVB3 replication by up to 11 orders of magnitude. In
addition to virus-neutralization capacity, we cannot rule out
other antiinflammatory effects of sCAR-Fc. Other decoy
receptor Fc fusion proteins (eg, CD55-Fc) and purified
pooled immunoglobulins have been shown to decrease myo-
cardial lesion area, inflammation, viral replication, and viral
progeny synthesis in CVB3 infection in vivo; however, these
were not as effective as sCAR-Fc.13,25,27 CAR has also been
reported to bind human IgG and IgM, which suggests a
further role for CAR in immune system interactions.28 Future
studies examining the ability of sCAR-Fc to modulate car-
diomyopathy in mouse models by other nonenteroviral patho-
gens will be needed to address this possibility.
Extension of the efficacy of sCAR-Fc beyond 24 hours
after CVB infection may be achieved by combining viral
neutralization with potent antiinflammatory therapies (for
example, targeting proinflammatory cytokines, which have
also been shown to be potent in inhibiting CVB3-induced
myocarditis29,30). Another potential approach would be to
combine sCAR-Fc with RNA interference that specifically
targets intracellular CVB3 during replication. In this context,
we have shown that small hairpin RNAs directed against
CVB3 RNA-dependent RNA polymerase were capable of
increasing systolic and diastolic function in CVB3-infected
animals.19
The safety of viral vectors plays an important role in gene
therapy applications. AdG12 treatment did not induce side
effects in CVB3-infected or uninfected animals. Furthermore,
because AdG12 is a first-generation AdV, its presence in the
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body is self-limited to several weeks.31 Moreover, the
doxycycline-dependent control of sCAR-Fc expression in
AdG12 enables on/off switching and confers the ability to
shut off transgene expression at any point after delivery,
thereby further increasing its safety. It is a hallmark of
AdG12 that there is no leaky sCAR-Fc expression in the
absence of the inducer drug, doxycycline. This was achieved
through the use of improved key components of the Tet-On
gene expression system, the second-generation transactivator
(rtTA-M2) and a new response promoter (tight1). Each was
shown to be able to reduce background activity of the Tet-On
system,21,22 but in contrast to the results presented here, the
use of rtTA-M2 with the original tetracycline-response pro-
moter, TRE, still resulted in leaky expression of the Tet-On
system in the context of AdVs.32,33 The resistance of tight1 to
nonspecific transactivation may be responsible for the lack of
leakiness of AdG12. Moreover, the use of improved compo-
nents of the Tet-On system enables side-by-side insertion of
cytomegalovirus-promoter–driven rtTA-M2 and tight1-pro-
moter–driven sCAR-Fc expression cassettes into the adeno-
viral E1 region, thereby simplifying the construction of
doxycycline-regulated AdVs.
Host immune responses often prevent readministration of
an AdV of the same serotype.34 This may limit the potential
clinical utility of our proof-of-concept approach in cases in
which repeated AdV administration would be necessary, eg,
to extend the treatment period. However, administration of
AdVs derived from different serotypes,35 or the use of
significantly less immunogenic vectors that are derived from
adeno-associated virus, is an available tactic to overcome this
limitation.
In conclusion, here we show therapeutic efficacy in treat-
ing CVB3 myocarditis with sCAR-Fc delivered from a
pharmacologically regulated AdV. The treatment was highly
efficient, without clinically observable side effects, and led to
improved hemodynamics and heart function in CVB3-
infected animals. For the purpose of the present study, the
chosen sample sizes were appropriate to document statistical
significance; however, if the prognostic relevance of this
treatment, including survival changes, is to be investigated in
the future, considerably larger study groups must be used.
The combination of the sCAR-Fc approach with gene therapy
methods represents a promising new approach for treatment
of cardiac CVB3 infections.
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CLINICAL PERSPECTIVE
Group B coxsackieviruses (CVBs) are the prototypical agents of acute myocarditis in humans, but an effective targeted
therapy is not yet available. Acute enteroviral myocarditis may not lead to initial mortality but often results in the insidious
development of chronic dilated cardiomyopathy and terminal heart failure. Here, we analyze the therapeutic potential of
a soluble (s) virus receptor molecule against CVB3 myocarditis, delivered by use of a gene therapy approach. We generated
an inducible adenoviral vector (AdG12) for strictly drug (doxycycline)-dependent delivery of sCAR-Fc, a fusion protein
composed of the coxsackievirus-adenovirus receptor (CAR) extracellular domain and the carboxyl terminus of human
IgG1-Fc. After intravenous injection, AdG12 significantly improved systolic and diastolic function in CVB3-infected mice
if sCAR-Fc expression was pharmacologically induced in a prophylactic or therapeutic setting. Importantly, the
hemodynamics of animals treated with AdG12 were similar to those of healthy control animals. With respect to the
underlying pathomechanism, sCAR-Fc completely blocked (prophylactic) or strongly reduced (therapeutic) cardiac CVB3
infection and the resultant myocardial injury and inflammation. The strength of the cardioprotective effect and the
additional safety feature mediated by the strict drug dependency of the sCAR-Fc expression make this strategy a promising
approach for treatment of this life-threatening cardiac disease. It may also serve as a paradigm for analogous treatments
of other severe viral infections by systemic delivery of “virus-trap” proteins, generated either by vectors as described here
or by direct intravenous infusion of the encoded recombinant protein.
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SUPPLEMENTAL MATERIAL  
 
Supplemental Methods 
 
Construction of Adenoviral Shuttle Plasmids 
For construction of sCAR-Fc fusion protein, total cellular RNA was extracted from HeLa cells 
using TRIzol® Reagent (Invitrogen GmbH, Karlsruhe, Germany) following the manufacturer’s 
instructions. RNA was reverse transcripted by the use of Superscript RTase (Invitrogen, 
Carlsbad, USA, CA). The extra cellular domain of human CAR was then amplified by PCR 
using NheI linked hCARs (5’ - cta gct agc tcg gca gcc agc atg gcg – 3’) and NotI linked 
human CAR specific primer B618 (5’ - ggc ggc cgc ttt att tga agg agg g – 3’). The resulting 
fragment was inserted via NheI/NotI into the plasmid pTorsten 1, upstream and in frame with 
the carboxy terminus of human IgG1 Fc coding region, leading to generation of sCAR-Fc 
fusion protein containing plasmid pTorsten-sCAR-Fc.  
For generation of a Dox-regulated sCAR-Fc expressing AdV, an expression cassette (TRE-
tight1-MCS-SV40pA) containing an improved Dox responsive tight1 promoter 2, a multiple 
cloning site (MCS) and a SV40 polyA signal was amplified with the primer pair P1-AatIII-
SpeIs (5’ - aac tga gac gtc taa cta gtc tca ggt tta ctc cct atc agt gat aga ga – 3’) and P2-XhoI-
XbaIas (5’ - ccg ctc gag gca gtc tag agc gag gaa gct aga ggc agt g – 3’) from pTRE-tight 
(Clontech, Palo Alto, CA, USA) and then cloned into pCR®4Blunt-TOPO (Invitrogen). The 
expression cassette was cut out with SpeI and XhoI and subcloned into the adenoviral 
shuttle plasmid pZS2-CMV-rtTA 3, in two opposite directions, via a singular XbaI site located 
downstream of the second-generation reverse tetracycline (tet)-controlled transactivator 
rtTA-M2 4 The plasmids generated were termed pAdTREtight-od-M2-G (opposite direction to 
that of the rtTA-M2 expression cassette) and pAdTREtight-sd-M2-R (same direction). sCAR-
 2
Fc was then amplified using the primer pair sCARFc-KpnIs (5’- cgg ggt acc cag cat ggc gct 
cct gct g – 3’) and sCARFc-MluIas (5’ - cga cgc gtc gcc att tag gtg acc act aat – 3’) in a 30-
cycle PCR with Pwo polymerase (Roche, Mannheim, Germany) from pTorsten-sCAR-Fc and 
cloned into pAdTREtight-od-M2-G and pAdTREtight-sd-M2-R via KpnI/MluI downstream to 
the TRE-tight1 promoter, resulting in the plasmids pAdG12-sCAR-Fc and pAdR4-sCAR-Fc. 
pAdG12-sCAR-Fctrunc was constructed as pAdG12-sCAR-Fc.  Different to pAdG12-sCAR-Fc 
in pAdG12-sCAR-Fctrunc a frameshift mutation at nucleotide position 9 (deletion of a cytosine) 
was inserted in sCAR-Fc leading to premature translation stop at amino acid 13. Therefore, 
the vector do not expresses sCAR-Fc.  
The correctness of all plasmids was confirmed by sequencing on an ABI 310 genetic 
analyzer (Applied Biosystems, Foster City, CA, USA). 
  
Development of Adenoviral Vectors 
The adenoviral shuttle plasmids pAdG12-sCAR-Fc, pAdR4-sCAR-Fc and pAdG12-
sCAR-Fctrunc were linearized with XbaI and ligated to the 5’ long arm of XbaI-digested E1- 
E3- adenovirus 5 mutant RR5. Transfection into HEK293 cells and propagation were done as 
described 5 generating the adenoviral vectors termed AdG12, AdR4 and AdG12trunc. All 
adenoviral constructs were tested for RCA contamination by PCR as described before 6 and 
the viral titres were determined using standard plaque assays on HEK293 cells. 
 
Northern Blot  
RNA was isolated using TRIzol® Reagent (Invitrogen GmbH) following the 
manufacturer’s instructions. 10 µg of total RNA were separated on a 1 % formaldehyde 
agarose gel and transferred to a Hybond N nylon membrane (Amersham Biosiences, 
Buckinghamshire, UK). After prehybridization, the membranes were hybridized with a 
[32P]dCTP-labeled single stranded antisense probe in ExpressHyb Solution (Clontech) 
following the manufacturer’s instructions. The probe was labelled in a PCR-like reaction as 
described previously 7 by use of primer B618 and a DNA fragment comprising the extra 
 3
cellular domain of human CAR as template. Hybridized filters were exposed to Kodak 
Biomax MS film (Integra Biosciences, Fernwald, Germany). The hybridization signal intensity 
was determined by phosphoimaging in a Fuji Film BAS-1500 imager (Fuji Photo Film, 
Dusseldorf, Germany). 
 
Western Blot 
For detection of sCAR-Fc protein, cells were transduced with viral vectors expressing 
sCAR-Fc or truncated sCAR-Fc and cultured with or without Dox. Supernatants were 
removed and collected, while cells were lysed with lysis buffer [20 mM Tris, pH 8, 10 mM 
NaCl, 0.5% (v/v) Triton X 100, 5 mM EDTA, 3 mM MgCl2]. After heating the cell-lysate and 
supernatants at 95° C for 5 min, protein was separated on NuPAGE 4-12% Bis-Tris gels 
(Invitrogen) under denaturating and reducing conditions and transferred onto a PVDF 
membrane (Bio-RAD Lab. Hercules, CA, USA). For detection of sCAR-Fc, the 
immunoreactivity membrane was incubated with anti-CAR monoclonal antibody RmcB 
(Upstate Biotechnology, Lake Placid, NY, USA) in a dilution of 1:200 or anti-GAPDH 
polyclonal antibody 1:7.500 (Chemicon International, Hofheim, Germany) for 1 h in 5 % dry 
milk/TBST. After washing, membranes were incubated with secondary goat-anti-mouse 
(primary antibody: RmcB) antibodies or swine-anti-rabbit antibodies (primary antibody: anti-
GAPDH) conjugated with peroxidase (DAKO GmbH, Hamburg, Germany) at a dilution of 
1:10.000. To detect the IgG1-Fc domain of sCAR-Fc, the membrane was stripped with 1.5 % 
glycine, 1 % SDS, 0.001 volume Tween 20 [pH 2] for 1 h at 55°C and reincubated with 
horseradish peroxidase conjugated sheep anti-human IgG antibody 1:500 (Amersham 
Bioscience) in TBST/5 % dry milk for 1 h. Detection by chemiluminescence was achieved 
using the ECL system (Amersham Bioscience). 
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Detection of sCAR-Fc Expression In Vivo by Use of the IgG specific Enzyme-linked 
Immunosorbent Assay 
Blood samples were taken from vector transduced animals by puncture of the vena 
facialis. The serum was separated by centrifugation at 4.000 rpm for 8 min and stored at -
80°C. The serum sCAR-Fc protein levels were determined by a human IgG ELISA kit (Bethyl 
Laboratories Inc., Montgomery, TX, USA).  
 
Virus Plaque Assay  
The amount of infectious CVB3 in HeLa cells was determined on monolayers of HeLa 
cells by agar overlay plaque assay, as described elsewhere 8. For in vivo analysis 
midventricular portions of the heart from CVB3 infected mice were homogenized in serum-
free DMEM, and subsequently analyzed by plaque assay. Results to be shown were gained 
by two independent experiments, each performed in duplicate. 
 
Histopathological Analysis 
The apical parts of the hearts were fixed in 4% formalin, embedded in paraffin, and 5-µm 
sections were cut and stained with hematoxylin and eosin (H&E) to assess myocardial injury 
and inflammation. To quantify myocardial damage comprising cardiac cell necrosis, 
inflammation, and scarring, we applied a myocarditis score of 0 to 4 as described 9 (score: 0, 
no inflammatory infiltrates; 1, small foci of inflammatory cells between myocytes; 2, larger 
foci >100 inflammatory cells; 3, ≤10% of the cross-section involved; 4, 10 to 30% of the 
cross-section involved). 
 
Haemodynamic Measurements 
Left ventricular (LV) function was analyzed using pressure volume loops. As 
described recently 10, the animals were anesthetized, intubated, and artificially ventilated. A 
1.2 F pressure-volume catheter (Scisense Inc., Ontario, Canada) was positioned in the LV 
for registration of LV pressure–volume (PV) loops in an open-chest model. Systolic function 
 5
was quantified by LV end-systolic pressure (LVP) (mmHg) and dP/dt max (mmHg/s). 
Diastolic function was quantified by analyzing dP/dt min (mmHg/s). 
 
In situ Hybridization 
CVB3 positive-strand RNA in tissues was detected using single-stranded 35S-labeled 
RNA probes which were synthesized from the dual-promoter plasmid pCVB3-R1. Control 
RNA probes were obtained from the vector pSPT18 11. Pre-treatment, hybridization, and 
washing procedures of dewaxed 5-μm paraffin tissue sections were performed as described 
previously 11. Slide preparations were subjected to autoradiography, exposed for 3 weeks at 
4°C, and finally counterstained with HE. 
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Supplemental Tables 
 
               Supplementary Table I 
 
 
A. Prophylactical approach – p-values for haemodynamic parameter comparisons 
 
 
 
Outcome parameters 
 LVP dP/dtmax dP/dtmin 
AdG12 (-Dox) vs. AdG12 (+Dox) p=0.0043 p=0.0043 p=0.0087
sham (+Dox) vs. sham (-Dox)  p=0.0043 p=0.0022 p=0.0649
 
 
B. Statistical data of haemodynamics of the prophylactical approach 
 
  LVP [mmHg] dP/dtmax [mmHg/s] dP/dtmin [mmHg/s] 
group N Q1 median Q3 mean STD Q1 median Q3 mean STD Q1 median Q3 mean STD 
AdG12 (-Dox) 6 43.68 45.77 47.90 45.39 2.73 1512.70 2071.95 2549.10 2057.90 490.24 -1464.40 -1295.90 -1025.00 -1310.23 330.30 
AdG12 (+Dox) 5 58.24 59.03 62.01 58.99 3.75 3388.00 3526.60 4072.70 3645.10 443.56 -2210.70 -2083.70 -1878.39 -2125.52 330.52 
sham (-Dox) 6 57.19 67.49 77.09 67.51 12.84 3168.90 4383.20 4992.40 4429.32 1287.57 -2656.50 -1941.32 -1477.80 -2117.39 713.47 
sham (+Dox) 6 43.15 45.84 50.27 46.60 5.54 1956.50 2333.25 2995.50 2428.50 490.44 -1825.50 -1094.70 -1049.50 -1330.49 437.41 
 
N=number of animals; Q1: 25th percentile; Q3: 75th percentile; STD= standard deviation 
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              Supplementary Table II 
 
 
 
A.     Therapeutical approach – p-values for haemodynamic parameter comparisons 
 
 
 
Outcome parameters 
 LVP dP/dtmax dP/dtmin 
AdG12 (+Dox, 0d) vs. AdG12trunc (-Dox) p=0.048 p=0.0303 p=0.0732
AdG12 (+Dox, 1d) vs. AdG12trunc (-Dox) p=0.1649 p=0.1282 p=0.1649
sham (+Dox) vs. sham (-Dox) p=0.0424 p=0.0121 p=0.0242
 
 
B.     Statistical data of haemodynamics of the therapeutical approach 
 
 
  LVP [mmHg] dP/dtmax [mmHg/s] dP/dtmin [mmHg/s] 
group N Q1 median Q3 mean STD Q1 median Q3 mean STD Q1 median Q3 mean STD 
AdG12 (+Dox, 0d) 5 61.29 74.83 93.03 76.38 19.18 3722.60 5182.13 6748.63 5214.19 1786.16 -5046.33 -3624.33 -2596.33 -3756.62 1418.03 
AdG12 (+Dox, 1d) 7 52.63 66.72 76.54 66.86 12.35 3062.30 3384.87 4819.50 3842.24 982.22 -3343.58 -2502.33 -2223.80 -2659.38 662.87 
AdG12trunc (-Dox) 7 47.92 54.39 68.18 56.82 10.32 2145.97 3106.57 4180.87 3011.62 918.34 -3087.37 -2217.43 -1555.10 -2212.04 745.68 
sham (+Dox) 4 50.59 61.30 72.10 61.35 12.63 2180.02 2760.45 3711.60 2945.81 964.82 -2877.27 -2214.78 -1682.47 -2279.87 716.20 
sham (-Dox) 7 70.94 79.89 84.35 78.66 8.27 4210.90 5101.47 6054.23 5076.71 854.92 -3949.27 -3455.37 -3272.75 -3505.97 471.88 
 
N=number of animals; Q1: 25th percentile; Q3: 75th percentile; STD= standard deviation 
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C. Therapeutical approach – p-values for CVB3 load in the heart comparisons 
 
 CVB3 titer
 
AdG12 (+Dox, 0d) vs. AdG12trunc (-Dox) p=0.0025 
AdG12 (+Dox, 1d)  vs. AdG12trunc (-Dox) p=0.0006 
 
 
D.      Statistical data of plaque assays of the therapeutical approach 
 
  CVB3 titer in PFU/mg heart 
group N Q1 median Q3 mean STD 
AdG12 (+Dox, 0d) 5 5.70 294.00 9090.00 14544.34 27549.81
AdG12 (+Dox, 1d) 7 5020.33 5438.05 109155.80 43906.66 56748.30
AdG12trunc (-Dox) 7 494395.00 648083.30 2421327.00 1175006.59 910721.67
sham (+Dox) 4 506405.20 574586.35 762618.65 634511.93 180380.50
 
N=number of animals; Q1: 25th percentile; Q3: 75th percentile; STD= standard deviation 
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Supplementary Figure I. On/off switching of sCAR-Fc expression.  
HeLa cells were transduced with AdG12 at a MOI of 2 and incubated with Dox (1 µg/ml). 
After 24 h (day 0) medium was replaced by fresh medium and cells were cultured for an 
additional 4 days with Dox (left panel) or without Dox (right panel). During this time, medium 
was replaced daily with fresh medium. sCAR-Fc was detected in both cells and medium by 
Western analysis using an anti-IgG-Fc antibody. GAPDH immunreactivity was used as 
loading control. sCAR-Fc complete disappeared in the cells and near complete disappeared 
in the supernatant on day four after withdrawal of Dox in comparison to the samples taken 
before. 
 
Supplementary Figure II. Inhibition of CVB3 replication in permissive HeLa cells 
through sCAR-Fc.  
(A) Inhibition of CVB3 replication as a function of AdG12 dose. HeLa cells were transduced 
with AdG12 (MOI 0 to 20) and cultured with Dox (1 µg/ml). Forty-eight hours later cell culture 
supernatant was harvested, pre-incubated with an MOI of 0.1 of CVB3 for 30 min at 4°C, 
deposited to the AdG12 transduced cells for 30 min and then replaced with fresh medium. 
CVB3 replication was analysed by plaque assays after 24 h of culture. 
(B) Influence of Dox dose on sCAR-Fc mediated inhibition of CVB3 replication. HeLa cells 
were transduced with AdG12 at a MOI of 5 and then cultured with Dox in different 
concentrations (0 - 1 µg/ml) for 48 h. CVB3 neutralization assays were performed as 
described under (A) above. 
(C) Measurement of Dox-dependent expression of sCAR-Fc in cell culture supernatant. HeLa 
cells were transduced and sCAR-Fc expression induced as described under (B) above. 
sCAR-Fc expression levels were measured in the cell culture supernatant by IgG ELISA.   
(D) Inhibition of CVB3 replication by AdG12 as a function of CVB3 doses escalation. HeLa 
cells were transduced with AdG12 at a MOI of 5 and incubated in the absence or presence of 
Dox (1 µg/ml) for 48 h. CVB3 neutralization assays were carried out as described under (A) 
above. 
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Supplementary Figure III. Systemic sCAR-Fc Gene Transfer Supports Inducible sCAR-
Fc Delivery in vivo 
(A) Kinetics of individual sCAR-Fc serum level after transduction of mice with AdG12. Balb/c 
mice (n=7) were injected intravenously with 3x1010 particles of AdG12. sCAR-Fc expression 
was induced and maintained in four animals by addition of 200 µg/ml Dox to the drinking 
water. The other three AdG12-transduced animals did not contain the drug. sCAR-Fc serum 
concentrations in AdG12 (+Dox) transduced animals roughly doubled from day 2 (254±29 
ng/ml) to day 5 (464±159 ng/ml), then decreased at day 8 (147±60  ng/ml), but expression 
did not decrease further when measured at day 14 (141±51 ng/ml). In the absence of Dox, 
sCAR-Fc serum levels were indistinguishable from levels in untransduced control mice. 
Histopathological examination of liver and heart samples did not show any signs of tissue 
damage and inflammation at various time points (not shown). 
(B) Kinetics of sCAR-Fc expression after delayed induction of sCAR-Fc. Balb/c mice (n=6) 
were injected intravenously with 1010 particles of AdG12. Measurement of sCAR-Fc 
expression in the serum revealed absence of sCAR-Fc in the serum two days after AdG12 
transduction. Dox (200 µg/ml) was than added to the drinking water to induce sCAR-Fc. 
sCAR-Fc serum levels reached 28.4 ng/ml 16 h after Dox treatment, increased to 552,7 
ng/ml at day 4 after induction and drop to 28.8 ng/ml at day 7 after induction.   
 
Supplementray Figure IV. sCAR-Fc prevents body weight loss in CVB3 infected 
animals. (A) Animals were treated as described in Figure 4A. (B) Animals were treated as 
described in Figure 5A. The values shown in A and B are mean values.  No mortality was 
observed in any of the groups. 
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